EGFR signaling defines Mcl-1 survival dependency in neuroblastoma

Cancer Biology and Therapy

Volumn 16, Issue 2, 2015, Pages 276-286

  Nalluri, Srilatha ^a,b   Peirce, Susan K ^a,b   Tanos, Rachel ^a,b   Abdella, Haneen A ^c   Karmali, Dipan ^b   Hogarty, Michael D ^d   Goldsmith, Kelly C ^a,b  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MIAMI CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ABT 737; Apoptosis; Bcl 2 antagonist; Bcl 2 homology proteins; Bim regulation; EGFR; Mcl 1

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BETA TUBULIN; BIM PROTEIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; SHORT HAIRPIN RNA; ABT-737; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; BIPHENYL DERIVATIVE; MEMBRANE PROTEIN; NITROPHENOL; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PMAIP1 PROTEIN, HUMAN; PROTEIN BINDING; SMALL INTERFERING RNA; SULFONAMIDE;

ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; MEMBRANE PROTEINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; NITROPHENOLS; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84924596524     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2014.1002333     Document Type: Article

References (34)

1. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27:1007-13; PMID:19171716; http://dx.doi.org/10.1200/JCO.2007.13.8925
2. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005; PMID:15927359
3. -2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13:1339-50; PMID:16763614; http://dx.doi.org/10.1038/sj.cdd.4401992
4. -2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res 2012; 72:2565-77; PMID:22589275; http://dx.doi.org/10.1158/0008-5472.CAN-11-3603
5. -2 family antagonists. Cell Death Differ 2010; 17:872-82; PMID:19893570; http://dx.doi.org/10.1038/cdd.2009.171
6. Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, Pawel BR, Hogarty MD. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009; 8; PMID:19556859
7. -1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67:782-91; PMID:17234790; http://dx.doi.org/10.1158/0008-5472.CAN-06-3964
8. -1 is neutralized. Cancer Cell 2006;10:389-99; PMID:17097561; http://dx.doi.org/10.1016/j.ccr.2006.08.027
9. -1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 2009; 7:549-56; PMID:19372583; http://dx.doi.org/10.1158/1541-7786.MCR-08-0358
10. -2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon- a and insulin-like growth factor 1. Cell Death Differ 2000;7:1244-52; PMID:11175262; http://dx.doi.org/10.1038/sj.cdd.4400758
11. Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005; 65:9868-75; PMID:16267010; http://dx.doi.org/10.1158/0008-5472.CAN-04-2426
12. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Current cancer drug targets 2009; 9:729-37; PMID:19754357; http://dx.doi.org/10.2174/156800909789271521
13. Meyers MB, Shen WP, Spengler BA, Ciccarone V, O'Brien JP, Donner DB, Furth ME, Biedler JL. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 1988; 38:87-97; PMID:2464605; http://dx.doi.org/10.1002/jcb.240380203
14. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007; 67:735-45; PMID:17234785; http://dx.doi.org/10.1158/0008-5472.CAN-06-2201
15. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001; 61:8-13; PMID:11196202
16. -1. J Biol Chem 2008; 283:9580-6; PMID:18178565; http://dx.doi.org/10.1074/jbc.M708426200
17. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-11; PMID:15329413; http://dx.doi.org/10.1073/pnas.0405220101
18. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-92; PMID:12242151; http://dx.doi.org/10.1016/S1535-6108(02)00127-7
19. -1-expressing myeloma cells. Blood 2011; 118:1329-39; PMID:21659544; http://dx.doi.org/10.1182/blood-2011-01-327197
20. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003;278:18811-6; PMID:12646560; http://dx.doi.org/10.1074/jbc.M301010200
21. Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ. Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases7rdquo; that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 2004; 279:8837-47; PMID:14681225; http://dx.doi.org/10.1074/jbc.M311578200
22. Mouhamad S, Besnault L, Auffredou MT, Leprince C, Bourgeade MF, Leca G, Vazquez A. B cell receptor-mediated apoptosis of human lymphocytes is associated with a new regulatory pathway of Bim isoform expression. J Immunol 2004; 172:2084-91; PMID:14764673; http://dx.doi.org/10.4049/jimmunol.172.4.2084
23. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45(3):279-84; PMID:23334666; http://dx.doi.org/10.1038/ng.2529. Epub 2013 Jan 20
24. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2008; 26:4921-7; PMID:18794549; http://dx.doi.org/10.1200/JCO.2007.15.2306
25. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005; 23:6172-80; PMID:16135484; http://dx.doi.org/10.1200/JCO.2005.11.429
26. Cao X, Zhu H, Ali-Osman F, Lo HW. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Molecular cancer 2011; 10:26; PMID:21388543; http://dx.doi.org/10.1186/1476-4598-10-26
27. Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett 2010; 294:101-10; PMID:20153921; http://dx.doi.org/10.1016/j.canlet.2010.01.028
28. Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, Lai R, Wiestner A. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma 2008; 49:798-808; PMID:18398749; http://dx.doi.org/10.1080/10428190801910912
29. -1. Mol Cell Biol 2009; 29:6149-69; PMID:19805519; http://dx.doi.org/10.1128/MCB.01481-08
30. Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009; 8:3173-80; PMID:19934277; http://dx.doi.org/10.1158/1535-7163.MCT-09-0685
31. Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970; 30:2110-8; PMID:5459762
32. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986; 76:375-87; PMID:3456456
33. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent JM. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305:245-8; PMID:6888561; http://dx.doi.org/10.1038/305245a0
34. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58:5396-405; PMID:9850071